Type I Interferon Signature in Sjögren's Syndrome: Pathophysiological and Clinical Implications

Clin Exp Rheumatol. May-Jun 2019;37 Suppl 118(3):185-191. Epub 2019 Jul 11.

Abstract

Type I interferons (IFN) have long been recognised as mediators of innate immune defense mechanisms against viral threats. Robust evidence over the last 15 years revealed their significant role in the pathogenesis of systemic autoimmune diseases, including systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). Despite the progress, methods of detection, initial triggers, biological functions and clinical associations in the setting of autoimmunity remain to be fully clarified. As therapeutic options for SS are currently limited, neutralising specific targets of the type I IFN pathway seems a promising option. In this review we summarise the current evidence regarding the role of type I IFN in SS.

Publication types

  • Review

MeSH terms

  • Humans
  • Interferon Type I* / adverse effects
  • Interferon Type I* / genetics
  • Interferon Type I* / physiology
  • Sjogren's Syndrome* / etiology
  • Sjogren's Syndrome* / immunology
  • Sjogren's Syndrome* / pathology

Substances

  • Interferon Type I